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Abstract
Background: When stimulated by small molecular agonists, the A3 adenosine receptor (AR) mediates
cardioprotective effects without inducing detrimental hemodynamic side effects. We have examined
pharmacologically the protective properties of a multivalent dendrimeric conjugate of a nucleoside as a selective
multivalent agonist for the mouse A3AR.
Results: A PAMAM dendrimer fully substituted by click chemistry on its peripheral groups with 64 moieties of a
nucleoside agonist was shown to be potent and selective in binding to the mouse A3AR and effective in
cardioprotection in an isolated mouse heart model of ischemia/reperfusion (I/R) injury. This conjugate MRS5246
and a structurally related model compound MRS5233 displayed binding Ki values of 0.04 and 3.94 nM, respectively,
and were potent in in vitro functional assays to inhibit cAMP production. A methanocarba (bicyclo[3.1.0]hexane)
ring system in place of ribose maintained a North conformation that is preferred at the A3AR. These analogues also
contained a triazole linker along with 5’-N-methyl-carboxamido and 2-alkynyl substitution, previously shown to be
associated with species-independent A3AR selectivity. Both MRS5233 and MRS5246 (1 and 10 nM) were effective at
increasing functional recovery of isolated mouse hearts after 20 min ischemia followed by 45 min reperfusion. A
statistically significant greater improvement in the left ventricular developed pressure (LVDP) by MRS5246
compared to MRS5233 occurred when the hearts were observed throughout reperfusion. Unliganded PAMAM
dendrimer alone did not have any effect on functional recovery of isolated perfused mouse hearts. 10 nM
MRS5246 did not improve functional recovery after I/R in hearts from A3AR gene “knock-out” (A3KO) mice
compared to control, indicating the effects of MRS5246 were A3AR-specific.
Conclusions: Covalent conjugation to a versatile drug carrier enhanced the functional potency and selectivity at
the mouse A3AR and maintained the cardioprotective properties. Thus, this large molecular weight conjugate is
not prevented from extravasation through the coronary microvasculature.
Background
Polyamidoamine (PAMAM) dendrimers can serve as bio-
compatible polymeric nanocarriers of bioactive molecules
of interest. They are versatile in that their size, shape and
placement of functional groups can be customized for
various applications [1-5]. For example, dendrimers have
been studied for targeted drug and gene delivery [4-8] or
for use as experimental tools to carry markers to targeted
cells that express unique receptors [9-11]. Additionally,
the attachment of drugs to dendrimers can prevent their
premature degradation or even enhance tissue selectivity
[1]. Nucleoside derivatives that activate adenosine recep-
tors (ARs) can also be attached to dendrimers, which can
greatly improve potency or effectiveness of the nucleo-
side ligands [12-14].
In the present study, an agonist of the A3AR conju-
gated to a PAMAM dendrimer was characterized
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isolated mouse heart model of ischemia/reperfusion
(I/R) injury. The A3AR is one of four subtypes among a
G protein-coupled receptor (GPCR) family (A1,A 2A,
A2B and A3) that responds to extracellular adenosine
[15]. Adenosine levels are significantly increased during
ischemic stress, thereby activating ARs near the site of
injury [16-18]. Of the four subtypes, A1 and A3ARs pre-
sent in the heart are well known to mediate the cardio-
protective effects of adenosine [19-22]. However, unlike
the A1AR, when the A3AR is activated by selective ago-
nists, such as Cl-IB-MECA 1 (Figure 1), it does not induce
detrimental hemodynamic side effects, such as negative
chronotropy, inotropy and dromotropy [20,23-25].
There is a medicinal chemical challenge in designing
nucleosides that act as selective A3AR agonists across
species. We have reported a class of A3AR agonists that
are 5’-N-methyl-carboxamido adenosine analogues con-
taining a methanocarba (bicyclo[3.1.0]hexane) ring sys-
tem in place of ribose to maintain a preferred North (N)
conformation, but some of the analogues such as
MRS3558 2 were shown to display >1,000-fold selectivity
for the human (h) A3AR but not the mouse (m) and rat
A3ARs [26,27]. This is because the (N)-methanocarba
ring system is better tolerated at the A1AR in rodents
than in humans, thereby, reducing selectivity for rodent
A3ARs [26,27]. Thus, these agonists that are otherwise
very selective in human are of limited use in rodent mod-
els. However, by varying substituents on the N
6 and C2
positions in the same structural series, species indepen-
dent A3AR selectivity was restored, especially in analo-
gues containing a 2-alkynyl (C≡C) group [27]. In the
present study, we have applied the principle of enhance-
ment of mA3AR selectivity of 2-alkynyl analogues to
chain extended structures. Specifically, the dialkyne 5
contains a second alkynyl group at the terminal position
for conjugation by click chemistry (Cu(I)-catalyzed 1,3-
dipolar cycloaddition reaction) to an azido derivatized
PAMAM dendrimer 4b to produce a GPCR-Ligand Den-
drimer (GLiDe) conjugate. The click precursor 5 also
served as an intermediate for the model compound 3.
Both 3 and the corresponding multivalent GLiDe conju-
gate MRS5246 6 were pharmacologically characterized at
mouse ARs, and it was determined whether binding and
functionality were affected by conjugation. Then, the car-
dioprotective effects of these monomeric and polymeric
A3AR agonists were evaluated utilizing isolated mouse
hearts in a Langendorff-perfusion system.
Results
Agonist structures and competition binding
We characterized the mAR binding of a GLiDe conju-
gate, MRS5246, and an unconjugated, structurally
related monomer agonist, MRS5233 3. The GLiDe con-
jugate MRS5246 was synthesized, as reported [13,14], by
covalently conjugating a precursor monomer, MRS5221
5, onto a fourth generation (G4) fully-substituted azido
PAMAM dendrimer precursor 4b (Figure 1). The
monomeric compound, MRS5233 3,m i m i c k e dt h e
structure of the modification of MRS5221 5 after conju-
gation to the dendrimer. Thus, the Cu(I)-catalyzed click
reaction forms a triazole from the combination of an
azido group (on the PAMAM) and a terminal alkyne
(on the nucleoside).
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Figure 1 Chemical structures of nucleoside and dendrimer derivatives. MRS5221 5 is a 5’-N-methyl-carboxamido adenosine analogue with a
(N)-methanocarba ring system that served as a synthetic precursor for the conjugation to an azide-functionalized G4 PAMAM dendrimer 4b to
synthesize the GLiDe conjugate MRS5246 6. The monomer, MRS5233 3 contained a 2-alkynyl chain similar to MRS5221, but also contains a
triazole linker group present in the PAMAM conjugate 6. MRS5401 4a is a closely related unliganded PAMAM precursor molecule.
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determined that the GLiDe conjugate, MRS5246, and the
monomer, MRS5233, both bind with significantly higher
affinity to the mA3AR than to the mA1AR by 359- and
169-fold, respectively (Table 1 & Figure 2A and 2B).
When comparing the selectivity of these agonists at the
mA3AR, the GLiDe conjugate MRS5246 showed a 98.5-
fold higher affinity than the monomer MRS5233 (Table 1,
Figure 2C).
cAMP functional assays
cAMP assays in HEK293 cells overexpressing recombinant
mARs were utilized to determine the potency, expressed as
IC50, of MRS5246 and MRS5233. Both MRS5246 and
MRS5233 were full agonists and highly selective for the
mA3AR in comparison to the mA1AR (Figure 3A and 3B).
In fact, MRS5233 at 100 μM was inactive at the mA1AR.
When the conjugate MRS5246 was compared to the mono-
mer MRS5233 in activating the A3AR, the conjugate was
200-fold more potent (0.02 nM vs. 4.0 nM) (Figure 3C).
Isolated mouse heart I/R experiments
MRS5246 and MRS5233 were tested for effects on func-
tional improvement in isolated mouse hearts subjected to
global ischemia and reperfusion. The agonists were
infused into the coronary circulation of the hearts for 10
min immediately before 20 min of global ischemia. The
functional recovery parameters (left ventricular developed
pressure [LVDP], rate of contraction [dP/dtmax], rate of
relaxation [dP/dtmin], and coronary flow [CF; mL/min/g])
of the hearts were assessed throughout reperfusion and
after 45 min of reperfusion and compared to those of con-
trol hearts.
First, it was confirmed that the nearly fully azide-deri-
vatized PAMAM dendrimer precursor not bearing any
nucleoside moieties, MRS5401 4a (Figure 1), did not
invoke any functional effects. There was no improvement
of functional recovery following I/R after the hearts were
exposed to ≤100 nM MRS5401 (Figure 4). However, the
monomeric agonist, MRS5233, and GLiDe conjugate,
MRS5246, evoked improved functional recovery com-
pared to control in a concentration-dependent manner
(Figures 5 and 6). MRS5246 provided marginally better
improvement compared to MRS5233 at both 1 and 10
nM. MRS5246 at the lower concentration of 1 nM
produced a statistically significant improvement in the
recovery of LVDP throughout reperfusion whereas an
equivalent concentration of MRS5233 did not. Thus,
MRS5246 exhibited greater potency at providing
ischemic protection. 10 nM MRS5246 was also infused
into hearts from A3KO mice and subjected to I/R. There
was no effect on functional improvement in these hearts
compared to control hearts (Figure 7).
Discussion
PAMAM dendrimers are biocompatible polymers with
extensive and advantageous applications in drug delivery
in vivo.P r e v i o u sd a t ah a v es h o w nG L i D ec o n j u g a t e sa n d
other nanoconjugates to acquire beneficial pharmacologi-
cal characteristics, such as increased receptor affinities,
increased potency and/or increased selectivity in compar-
ison to monomeric ligands [1-5,9-14]. These nanocarriers
may also provide pharmacokinetic and pharmacodynamic
advantages, such as impeded metabolic degradation or
tissue selectivity [1-5,9-14]. In our case, the drug is not
intended for cleavage from the carrier at the site of
action. The extracellular intact conjugate holds the rele-
vant biological activity and can benefit from the versati-
lity of the PAMAM dendrimers for further derivatization
or structural modification as needed for the biological
application.
For the present studies, an adenosine analogue
(MRS5233) selective for the hA3AR, but modified to pos-
sess improved selectivity for the A3AR in mouse, was char-
acterized in mouse model experiments [27]. This
compound was also investigated as a mA3AR agonist
pharmacophore for conjugation to a G4 PAMAM dendri-
mer for the synthesis of the GLiDe conjugate, MRS5246.
It was determined that both agonists, MRS5246 and
MRS5233, bind with high affinity to the mA3AR with Ki
values of 0.04 and 3.94 nM, respectively. In comparison
to other AR subtypes, they are highly selective for the
mA3AR. This includes high selectivity over the A1AR, the
subtype to which these analogues might be more likely to
bind compared to A2A or A2BARs. It was further deter-
mined that MRS5233 and MRS5246 are highly potent in
in vitro functional assays to inhibit cAMP production via
A3AR-induced activation of Gi proteins compared to that
of the A1AR. MRS5246 showed an IC50 of 0.02 nM at the
mA3AR compared to 577.6 nM at the mA1AR (ratio of
Table 1 Binding affinities calculated from radiologand ([
125I]I-AB-MECA) binding experiments
Agonist mA3AR,
Ki or Kiapp (nM)
mA1AR,
Ki or Kiapp (nM)
Selectivity (A1 /A3)
MRS5246 0.04 ± 0.002 14.35 ± 4.35 359-fold
MRS5233 3.94 ± 0.31 665 ± 70 169-fold
98.5-fold increase
(MRS5233/MRS5246)
46.3-fold increase
(MRS5233/MRS5246)
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Page 3 of 12Figure 2 Competition binding assays. Increasing concentrations of MRS5246 or MRS5322 were added to compete for binding with [
125I]I-AB-
MECA to determine binding affinity, expressed as Ki or Kiapp, to recombinant mARs on HEK293 cell membranes. A & B, Both MRS5246 and
MRS5322 bind to the mA3AR with much higher affinity than to the mA1AR. C, binding curves from mA3ARs to compare and show MRS5246
binds with much higher affinity than MRS5322 at the mA3AR.
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Page 4 of 12Figure 3 cAMP functional assays. Increasing concentrations of MRS5246o rM R S 5 3 2 2w e r ea d d e dt oa c t i v a t em A 1 or mA3ARs to inhibit
forskolin-stimulated cAMP production. A & B, both compounds are much more potent at the mA3AR than at the mA1AR. C, curves from mA3ARs
to compare and show MRS5246 was much more potent than MRS5233 at the mA3AR.
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Page 5 of 1228,880), while MRS5233 resulted in an IC50 of 4.0 nM at
the mA3AR and lacked inhibition at the A1AR up to 0.1
mM. Therefore, these compounds promised to be excel-
lent candidates for the study of cardioprotection by
A3AR activation in mouse models.
In comparing the activities of the two compounds,
MRS5246 possessed a much higher affinity to the
mA3AR compared to the monomer, MRS5233, by 98.5-
fold. The conjugated MRS5246 was also 200-fold more
potent A3AR agonist than the monomer, MRS5233, in an
in vitro cAMP assay. These findings are comparable to
previous findings with other GLiDe conjugates, which
significantly improved affinity and potency over the
unconjugated monomeric agonists [13,14,28]. The Ki
values of these agonists in binding to hARs have been
reported and indicate that 3, 5,a n d6 are all A3AR-selec-
tive [13,14,27]. For example, the triazole derivative 3 dis-
played Ki values of 22.3 ± 1.6 nM and 2440 ± 320 nM at
the hA3AR and hA2AAR, respectively, and at 10 μM
inhibited only 12 ± 4% of the radioligand binding at the
hA1AR [13,14]. Thus, the model compound 3 binds to
the mA3AR with 5.7-fold greater affinity than to the
hA3AR. The conjugate 6 binds to the mA3AR with 3.5-
fold greater affinity than to the hA3AR. In comparison to
the A1AR, the A3AR selectivity of 6 is slightly greater in
the mouse (359-fold) than human (161-fold).
The binding and in vitro cAMP assays were performed
under unrestricted solution conditions, with no interven-
ing biological barriers such as would be encountered in
vivo. There is limited hindrance in these experiments for
the PAMAM dendrimers, which range in size of around
~45 Å in diameter for a G4 dendrimer [29]. This size
estimate does not include the addition of the covalently
conjugated agonist moieties, which would further
increase the diameter. However, in vivo,t h eG L i D ec o n -
jugates must reach the myocardial targets by extravasa-
tion from the coronary microvasculature. It has been
determined that the extravasation process of PAMAMs
alone is dependent on the size and maybe even charge of
the compounds [29]. These authors found that with each
size-increasing generation of PAMAM dendrimers, up to
the G4, there was a weight- and size-dependent decrease
Figure 4 PAMAM control dendrimer, MRS5401, alone did not influence functional recovery of isolated mouse hearts subjected to 20
min ischemia/45 min reperfusion up to a concentration of 100 nM. The graph shows recovery of LVDP during reperfusion as a percent of
paced baseline. The inset shows the percent recovery of the hearts at 45 min reperfusion for the rates of relaxation, contraction and coronary
flow. There were no differences compared to control hearts not exposed to MRS5401.
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Page 6 of 12Figure 5 The monomeric analogue, MRS5233, was effective at increasing functional recovery of isolated mouse hearts after 20 min
ischemia/45 min reperfusion compared to control at 1 (A) and 10 nM (B). 1 nM MRS5233 showed a trend in improving LVDP over control
during reperfusion, while there was significant improvement with 10 nM MRS5233. The insets show that the recovery of rates of relaxation and
contraction at 45 min reperfusion was significantly better than that of control hearts at both concentrations.
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Page 7 of 12Figure 6 The GLiDe conjugate, MRS5246, was effective at increasing functional recovery of isolated mouse hearts after 20 min
ischemia/45 min reperfusion compared to control at 0.1 (A), 1 (B), and 10 nM (C). Both 1 and 10 nM concentrations of MRS5246 evoked
significant improvement of LVDP over control during reperfusion. The insets show that there was also significantly better recovery of rates of
relaxation and contraction at 45 min reperfusion than that of control hearts at both concentrations.
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steady decrease in the rate of extravasation from the G1
to G3 dendrimers, but an especially high decrease
between G3 and G4 [29].
However, in light of these intuitive results that greater
sizes offer hindrances, the Langendorff isolated heart
experiments showed that the GLiDe conjugate, MRS5246,
was just as, maybe even more, effective than the mono-
meric agonist in generating cardioprotection after I/R.
MRS5246 and MRS5233 were effective in a concentration-
dependent manner, where both showed significant protec-
tion starting at one nanomolar, and the effects were
greater at 10 nM. The percentage of improvements after
45 min of reperfusion was marginally greater for the
GLiDe conjugate at these concentrations. However, the
multivalent conjugate MRS5246 (1 nM) was more effective
than the monomer MRS5233 in improving LVDP over
control when observing the hearts throughout reperfusion.
Since we did not obtain a direct measure of cell death, it
s h o u l db en o t e dt h a tw ed on o tk n o ww h e t h e rt h e
improvements in functional recovery with agonist treat-
ment observed in the isolated mouse heart studies resulted
from protection against reversible injury (i.e., myocardial
“stunning”) and/or necrotic cell injury (i.e., infarction).
Conclusions
Conjugation of an A3AR-specific agonist to a PAMAM
dendrimer indeed greatly improved its in vitro affinity
and potency compared to the monomer itself. However,
despite the greatly increased size and bulkiness of the
GLiDe conjugate, it retained its potent cardioprotective
effects in mouse isolated perfused hearts, and it was
more effective than its smaller monomeric counterpart.
This implied that the barrier for extravasation from the
coronary microvasculature did not prevent passage of at
least some of the polymeric conjugate.
T h e s ef i n d i n g sp r o v i d ea s s u r a n c et h a tG L i D ec o n j u -
gates warrant further study in vivo of their very impor-
tant advantages over the unconjugated ligands. Because
ARs are expressed throughout the body and produce dif-
ferent effects, these specific mA3AR dendrimers can be
utilized to investigate methods to specifically target them
to the myocardium, perhaps on the basis of an antibody
complex. It has been determined that there is enhanced
Figure 7 Hearts from A3KO mice exposed to 10 nM MRS5246 did not show improved functional recovery after I/R compared to
control indicating the effects of MRS5246 were mA3AR-specific.
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dendrimers [30]. Protection of A3AR agonists against
early degradation in the form of GLiDe conjugates is
essential, especially considering the findings that A3AR
agonists may be cardioprotective, but some are very
short-lived. It is also becoming evident that GPCRs,
including ARs, may function more efficiently as homo-
or heterodimers [31-33]. These dendrimers, which pro-
vide ways to control the dimensions or spacing between
the functional groups, will be important for studying ARs
as oligomers. Additionally, other GPCR-binding ligands,
such as opioids, also provide cardioprotection, in addition
to findings that adenosine and opioid receptors can
dimerize [34]. These dendrimeric carriers can be utilized
to carry multiple agents to targeted tissues as enhanced
cardioprotectants.
Methods
Chemical synthesis and reagents
Adenosine agonists 3, 5,a n d6 were synthesized as
reported [13,14]. Adenosine agonists were first dissolved
in DMSO and stored at -20 °C as stock solutions. PSB603
was purchased from Tocris Biosciences (Ellisville, MO),
CVT-6883 was obtained from ChemieTek (Indianapolis,
IN), and adenosine deaminase (ADA) was from Roche
Applied Science (Indianapolis, IN). All other chemicals
were from from Sigma-Aldrich (St. Louis, MO).
Radioligand competition assays
The competition assays were performed as previously
published [35]. Briefly, to prepare the membranes,
HEK293 cells stably expressing recombinant mARs were
harvested and homogenized in 10 mM Na
+-HEPES buf-
fer (pH 7.4) with 10 mM EDTA and 0.1 mM benzami-
dine. The cell lysates were centrifuged (35,000 × g for 25
min; 4°C), and the pellets were resuspended in 10 mM
Na
+-HEPES buffer (pH 7.4) with 1 mM EDTA and 0.1
mM benzamidine. The suspensions were homogenized
and centrifuged again (35,000 × g for 25 min; 4°C). The
resultant pellets were re-suspended in buffer containing
10% sucrose and stored at -80°C until use.
For the radioligand binding assays, 50 μg cell mem-
branes (100 μL) were incubated in 10 mM Na
+-HEPES
buffer (pH 7.4) with 5 mM MgCl2,5U / m LA D A ,a n d
[
125I]I-AB-MECA as radioligand. The competing ligands
of interest were added at various concentration ranges.
The IC50 values were calculated using nonlinear regression
analysis by fitting the data to the following equation:
binding = nonspeciﬁc binding+

total binding - nonspeciﬁc binding

/

1+1 0 x-logIC50

Inhibition constant (Ki) values were calculated using
the Cheng-Prusoff equation [36]. The concentration of
MRS5246 reflected the concentration of the dendrimeric
complex, not the individual ligand moieties. Therefore,
all binding Ki values of this dendrimer are to be consid-
ered as Kiapp values.
cAMP functional assays
The assays of cAMP (3’,5’-cyclic adenosine monopho-
sphate) were performed utilizing a modified protocol pub-
lished by Nordstedt and colleagues [37], whereby cAMP
content was determined by displacement of [
3H]cAMP
binding to regulatory subunits of protein kinase A in
bovine adrenal extracts. HEK293 cells heterologously
expressing the mA3AR were prepared by plating 2.5 × 10
5
cells per well in 24-well plates and cultured overnight in
complete media (DMEM with 10% fetal bovine serum/
PenStrep/0.4 mg/mL G418) at 37°C. The cells were
washed with DMEM/25 mM HEPES (pH 7.4) followed by
incubation in DMEM/25 mM HEPES containing 20 μM
Ro 20-1274 (phosphodiesterase inhibitor), 1 U/mL ADA
and a combination of two selective A2BAR antagonists
(300 nM CVT-6883 and 300 nM PSB603) at 37°C for
15 min. Forskolin (20 μM) to induce cAMP production
and the test compounds of interest were then simulta-
neously added. A concentration range of ligands or den-
drimer conjugates was tested in triplicate to inhibit cAMP
production via activation of A1 or A3 ARs. After incuba-
tion at 37°C for 15 min, the media was aspirated, and the
cells were lysed with 200 μL ice cold 0.1 M HCl on a sha-
ker at 4°C for 30 min. The lysates were collected and
cAMP levels in the acid extract were determined by com-
petitive binding assays as follows. Each lysate sample and
cAMP standard were diluted in 0.1 M HCl and subse-
quently transferred to polypropylene tubes (100 μL). [
3H]
cAMP (12,000 cpm/100 μL water/tube) and protein
extract from bovine adrenal tissue were then added (240
μg adrenal protein/tube at a concentration of 0.6 μg/μL, in
the binding protein buffer: 100 mM Tris-HCl, 250 mM
NaCl, 10 mM EDTA, 0.1% 2-mercaptoethanol, pH 8.0),
with the extract isolated from bovine adrenal glands as
described by Nordstedt, et al.[ 3 7 ]t op r o v i d et h ec A M P
binding substrate. The samples were incubated at 4°C for
2.5 hours and harvested through GF/C glass microfiber fil-
ters using a cell harvester (Brandel, Gaithersburg, MD)
and counted in scintillation cocktail. The results were
interpolated from standard curves obtained from known
concentrations of cAMP standards.
Animals
All experiments were performed with male mice (10-12
weeks of age, weighing ~25-30 g). Wild-type C57BL/6J
mice were purchased from Jackson Laboratories (Bar
Harbor, Me). A3KO mice were generated by embryonic
stem cell targeting and genotyped by Southern blotting
[38]. A3KO mice used had been transferred to the
C57BL/6 genetic background by backcrossing greater
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Page 10 of 12than 12 generations. All experiments involving animals
were approved by the Institutional Animal Care and Use
Committee at the Medical College of Wisconsin and
complied with the procedures established by the National
Institutes of Health G u i d ef o rt h eC a r ea n dU s eo f
Laboratory Animals.
Langendorff-Perfused Isolated Mouse Heart Model of I/R
Isolated mouse heart experiments were performed as
described previously [20,23]. In brief, hearts were isolated
from C57Bl/6J male mice and cannulated via the aorta
and perfused in a retrograde fashion by Krebs-Henseleit
buffer. Pressure measurements were obtained via a fluid-
filled balloon inserted into the left ventricle via the mitral
valve and connected to a pressure transducer. The hearts
were immersed in warmed perfusion buffer to maintain
the hearts at 37°C, and the balloons were inflated to
achieve constant end-diastolic pressures of 5 to 10 mm
Hg.
The hearts were perfused for 20 min to achieve stabiliza-
tion and then paced at 420 beats/min for baseline func-
tional measurements. Global ischemia was achieved by
closing an in-line stopcock to stop perfusion for 20 min
followed by 45 min of reperfusion by re-opening the stop-
cock. To examine the effect of the ligands and dendrimer
conjugates on functional recovery, the hearts were per-
fused with buffer containing the indicated concentrations
of compounds for 10 min immediately before ischemia.
Data Analysis
All data are reported as means ± S.E.M. Functional recov-
ery data in the isolated heart studies were analyzed by
two-way repeated measures ANOVA. If global tests
showed a main effect, post-hoc contrasts between treat-
ments were performed with Student’s t test for unpaired
data with the Bonferroni correction. Left ventricular func-
tional recoveries at 45 min of reperfusion were compared
using one-way analysis of variance followed by Student’s t
test with the Bonferroni correction or an unpaired Stu-
dent’s t test, as appropriate. P < 0.05 was statistically
significant.
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